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Background: Aim of this study is to analyze the incidence and risk factors for early postoperative
morbidity and mortality that occur after gastric carcinoma surgery.
Materials and methods: All consecutive patients with gastric adenocarcinoma resected with curative
intent between 2005 and 2011 were included to a retrospective analysis. Patient, disease and operation
related parameters were questioned as risk factors for postoperative morbidity and mortality.
Results: A total of 160 patients (103 [64.8%] male and the average age was 62.4  11.5) were abstracted.
Early postoperative morbidity, operation related morbidity and mortality were observed in 46 (28.7%), 31
(19.4%) and 19 (11.9%) cases, respectively. No other factors but ASA score was found to be a risk factor for
overall morbidity (p ¼ 0.021 and 0.033 in univariate and multivariate analyses, respectively). The inci-
dence of anastomotic leak was increasing in patients who received a D2 dissection in univariate analysis
(p ¼ 0.039), but not in multivariate calculation. There were no factors effecting surgical site infection risk.
Although univariate analysis revealed that age over 70 (p ¼ 0.008), ASA score (p ¼ 0.018), operation time
(p ¼ 0.032), D2 dissection (p ¼ 0.026) and type of anastomosis (p ¼ 0.023) were effecting the risk for
early mortality, multivariate analysis showed that age was the only risk factor (p ¼ 0.005).
Conclusion: Current study has revealed that early morbidity and mortality are not rare after gastric
cancer surgery with curative intent. Since multivariate analyses have revealed that ASA score and older
age may be only risk factors for postoperative morbidity and 30-day mortality, respectively; it may be
logical to consider these factors during the preoperative decision making in patients with gastric cancer.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gastric carcinomas are the second mostly seen cause for
cancer related death all around the world.1 An R0 surgical
resection is the only proven curative treatment modality in case
of a gastric carcinoma.2e4 However, in spite of all radical resection
attempts and developing adjuvant oncologic treatment tech-
niques, gastric carcinomas have a poor prognosis except for early
stage gastric carcinomas, which is a rare condition. Although
centers specialized on gastric surgery give better results, 5 year
survival expectancy is as poor as 23% in European countries.5urgery, Kartal Education and
A Blok D:6, 41524 Kocaeli,
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ciates Ltd. Published by Elsevier LtSince patients are generally being diagnosed at advanced stages
in western world, only 30e60% of those are considered to be
candidates for a curative surgery.6e8 Even though 5 year survival
expectancy has increased at a certain level with the help of
screening programs and discovering early stage disease more
often in some locations, particularly in Japan; prognosis of the
gastric carcinomas at an advanced level is poor in these countries
as well.9,10 D2 dissection in gastric carcinoma treatment is
accepted as a standard lymphadenectomy technique except for
early period gastric carcinomas in the Far East, and this has
showed survival advantages in many studies.11e13 However, two
prospective randomized studies have terminated the controversy
on whether or not D2 dissection leads to a survival advantage, but
generally revealed that extended dissection may be associated
with higher morbidity and mortality.14e18
Gastric cancer surgery is associated with high risks for
postoperative morbidity and mortality; two prospectived. All rights reserved.
Table 1
Postoperative complications and 30-day mortality.
Occurrence of
morbidity (n ¼ 46)
Related deaths
(n ¼ 19)
Surgical complications 31(19%) 9(5.6%)
Leakage (anastomotic and
duodenal stump)
17(10.6%) 9(5.6%)
Surgical site infection 8(5%) 0
Miscellaneousa 6(3.7%) 0
Non-surgical complications 15(9.4%) 10(6.2%)
Cardiac (infarction or insufﬁciency) 7(4.4%) 7(4.4%)
Pulmonary (emboli or infection) 4(2.5%) 2(1.2%)
Acute tubular necrosis 1(0.6%) 1(0.6%)
Toxic hepatitis 1(0.6%) 0
Miscellaneousb 2(1.2%) 0
a Pancreatic ﬁstula (n ¼ 3), prolonged ileus (n ¼ 2), and postoperative prolonged
hemorrhagic drainage (n ¼ 1).
b Serebrovascular accident (n¼ 1) and infection of central venous catheter (n¼ 1).
Table 2
Univariate and multivariate analyses of the risk factors that may affect overall morbidity
n (%) Complication No complication
Age
70 50 (31.2%) 18 (36%) 32 (64%)
<70 110 (68.7%) 28 (25.4%) 82(74.6%)
Gender
Male 103 (64.8%) 31 (30.1%) 72 (69.9%)
Female 57 (35.2%) 15 (26.3%) 42 (73.7%)
Albumin level
3.5 37 (23.1%) 13 (35.1%) 24 (64.9%)
<3.5 123 (76.9%) 33 (26.8%) 90 (73.2%)
Severe anemia
Absent 43 (26.9%) 14 (32.5%) 29 (67.5%)
Present 117 (73.1%) 32 (27.3%) 85 (72.7%)
ASA score
1e2 91 (56.9%) 18 (19.8%) 73 (80.2%)
3e4 69 (43.1%) 28 (40.6%) 62 (59.4%)
Neoadjuvant chemotherapy
Required 15 (9.3%) 3 (20%) 12 (80%)
Not required 145 (90.7%) 43 (29.6%) 102 (70.4%)
DM
Present 24 (15%) 8(33.3%) 16(66.7%)
Absent 136 (85%) 38 (27.9%) 98 (72.1%)
Hypertension
Present 39 (24.4%) 8 (20.5%) 31 (79.5%)
Absent 121 (75.6%) 37 (30.8%) 84 (69.2%)
COPD
Present 8 (5%) 3 (37.5%) 5 (62.5%)
Absent 152 (95%) 43(28.3%) 109 (71.7%)
Intraoperative transfusion
Required 69 (43.2%) 24 (34.8%) 45 (65.2%)
Not required 91 (56.8%) 22 (22.2%) 69 (77.8%)
Tumor localization
Proximal 65 (40.6%) 20(30.8%) 45 (69.2%)
Distal 95 (59.4%) 26(27.4%) 69(72.6%)
Tumor stage
I 23 (14.4%) 8 (34.8%) 15 (65.2%)
II 38 (23.8%) 7 (18.4%) 31 (81.6%)
III 48 (30%) 15 (31.2%) 33 (68.8%)
IV 51 (31.8%) 16 (31.4%) 35 (68.6%)
Operation time
180 79 (49.4%) 18 (22.8%) 61 (78.2%)
<180 81 (50.6%) 28 (34.6%) 53 (65.4%)
Dissection width
D1 118 (73.7%) 28 (23.7%) 90 (66.3%)
D2 42 (26.3%) 18 (42.9%) 24 (67.1%)
Resection pattern
Subtotal 62 (38.7%) 17 (27.4%) 45 (73.6%)
Total 98 (61.3%) 29 (29.6%) 69 (70.4%)
Additional organ resection
Present 85 (53.1%) 31 (36.5%) 54 (63.5%)
Absent 75 (46.9%) 15 (25%) 60 (75%)
Reconstruction type
Roux-en Y 129 (80.6%) 34 (26.3%) 95 (73.7%)
Omega 31 (19.4%) 7(22.6%) 24(78.4%)
Abbreviations: ASA: anesthesia risk score deﬁned by American Anesthesiology Associati
Bold font style represents statistically signiﬁcant difference between groups, p < 0.05.
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dissections reported the complication and death rates as 43 and
46%, and 10 and 13%, respectively.14e18 Major complications may
be stated as duodenal perforation and anastomotic leakage,
bleeding, surgical site infections, pancreatitis, stenosis on the
anastomotic line and functional problems. With the development
of anesthesiology, postoperative care, interventional radiology
and operation techniques, these complications have been reduced
at a certain level; however, both surgical and non-surgical com-
plications of gastric carcinoma operations still create severe
problems after the operation. Thus, the aim of the current study is
to evaluate the single institution outcomes regarding the post-
operative complication and mortality incidences, and analyze the
risk factors that may be associated with these results..
Univariate p Multivariate p Wald Odds ratio
0.393
0.544
0.131 0.188 1.734 0.556
0.223 0.498 0.459 0.740
0.021 0.033 4.544 2.285
0.252
0.939
0.4
0.430
0.114 0.547 0.363 1.277
0.620
0.937
0.240
0.081 0.146 2.118 1.977
0.483
0.058 0.377 0.779 1.488
0.665
on; DM: diabetes mellitus; and COPD: chronic obstructive pulmonary disease.
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Institutional Ethics Board approved the design and content of the study prior to
data abstraction (Reference number: B104_ISM4340029/1009/13). A retrospective
chart review has been initiated for all consecutive patients with pathologically
conﬁrmed gastric adenocarcinoma, who received a resection with curative intent
between 2005 and 2011 in our department. Patients who underwent a palliative
resection or operation, were excluded.
Current study aims to evaluate the incidences and risk factors for postoperative
early morbidity and mortality after gastric carcinoma surgery. Postoperative
morbidity was categorized into two groups as surgical and non-surgical complica-
tions, and leakage and surgical site infections were analyzed in details. Anastomotic
and duodenal stump leaks were included in the term of leakage; and wound infec-
tion, abscess and eviseration were deﬁned as surgical site infection. Since it was a
signiﬁcant indicator for the success of the operation, factors lengthen the hospitali-
zationwere also analyzed. Finally, because it had the paramount signiﬁcance, 30-day
mortality was also evaluated regarding the incidence and risk factors. The following
patient, disease or treatment related factors were questioned in univariate andTable 3
Univariate and multivariate analyses of the risk factors that may affect anastomotic leak
n (%) Present Absent
Age
70 50 (31.2%) 5 (10%) 45 (90%)
<70 110 (68.7%) 12 (10.9%) 98 (89.1%)
Gender
Male 103 (64.8%) 12 (11.6%) 91 (88.4%)
Female 57 (35.2%) 5 (8.8%) 52 (91.2%)
Albumin level
3.5 37 (23.1%) 3 (8.1%) 34 (91.9%)
<3.5 123 (76.9%) 14 (11.4%) 109 (88.6%)
Severe anemia
Absent 43 (26.9%) 2 (4.6%) 41 (95.4%)
Present 117 (73.1%) 15 (12.8%) 102 (87.2%)
ASA score
1e2 91 (56.9%) 10 (11%) 81 (89%)
3e4 69 (43.1%) 7 (10.1%) 62 (89.9%)
Neoadjuvant chemotherapy
Required 15 (9.3%) 0 (0) 15 (100%)
Not required 145 (90.7%) 17 (11.7%) 128 (88.3%)
DM
Present 24 (15%) 2 (8.3%) 22 (91.7%)
Absent 136 (85%) 15 (11%) 121 (89%)
Hypertension
Present 39 (24.4%) 3 (7.7%) 36 (92.3%)
Absent 121 (75.6%) 14 (11.6%) 107 (88.4%)
COPD
Present 8 (5%) 0 (0) 8 (100%)
Absent 152 (95%) 17(11.2%) 135 (88.8%)
Intraoperative transfusion
Required 69 (43.2%) 6 (8.7%) 63 (91.3%)
Not required 91 (56.8%) 11 (12.1%) 80 (87.9%)
Tumor localization
Proximal 65 (40.6%) 8 (12.3%) 57 (87.7%)
Distal 95 (59.4%) 9 (9.5%) 86 (90.5%)
Tumor stage
I 23 (14.4%) 1 (4.3%) 22 (95.7%)
II 38 (23.8%) 6 (15.8%) 32 (84.2%)
III 48 (30%) 5 (10.4%) 43 (89.6%)
IV 51 (31.8%) 5 (9.8%) 46 (90.2%)
Operation time
180 79 (49.4%) 5 (6.3%) 74 (94.7%)
<180 81 (50.6%) 12 (14.8%) 69 (85.2%)
Dissection width
D1 118 (73.7%) 9 (7.6%) 109 (92.4%)
D2 42 (26.3%) 8 (19%) 34 (81%)
Resection pattern
Subtotal 62 (38.7%) 5 (8.1%) 57 (91.9%)
Total 98 (61.3%) 12 (12.2%) 86 (87.8%)
Additional organ resection
Present 85 (53.1%) 12 (14.1%) 73 (85.9%)
Absent 75 (46.9%) 5 (6.7%) 70 (93.3%)
Reconstruction type
Roux-en Y 129 (80.6%) 15 (11.6%) 114 (88.4%)
Omega 31 (19.4%) 2 (6.4%) 29 (93.6%)
Abbreviations: ASA: anesthesia risk score deﬁned by American Anesthesiology Associati
Bold font style represents statistically signiﬁcant difference between groups, p < 0.05.multivariate analyses: age (over or below 70 years), gender, preoperative albumin
level (below or over 3.5 gr/L), severe anemia (deﬁned as ‘present’ if the patient
required transfusion preoperatively), anesthesia risk score (as deﬁned by American
Anesthesiology Association [ASA]), requirement for neoadjuvant chemotherapy,
having a medical disease (diabetes mellitus [DM], hypertension and chronic
obstructive pulmonary disease [COPD]), requirement of intraoperative transfusion,
tumor location (proximal or distal) and stage, operation time (less or more than
180 min), width of dissection (D1 or D2), resection pattern (total or subtotal), addi-
tional organ resection and reconstruction type (omega and Roux-en Y anastomosis).
The data were evaluated in computer environment by using the program SPSS
17 for Windows (Chicago; SPSS Inc.). Continuous variables were deﬁned as means
and standard deviations or medians and ranges. Countable variables were deﬁned
with numbers and percentages. The mean of the variables were compared by using
Student’s t test, countable data were compared by using ChieSquare test or by
Fisher’s test if appropriate. The variables, which had a p value lower than 0.25 found
through the univariate analysis were accepted as candidates for multivariate anal-
ysis. Multivariate analyses were carried out by using logistic regression method.
When p values were lower than 0.05, they were accepted as statistically signiﬁcant.age.
Univariate p Multivariate p Wald Odds ratio
0.863
0.571
0.571
0.137 0.183 1.773 2.871
0.864
0.161 0.998 0.001 0.008
0.693
0.494
0.317
0.49
0.568
0.56
0.082 0.319 0.995 1.881
0.039 0.382 0.763 1.734
0.403
0.127 0.584 0.300 1.442
0.401
on; DM: diabetes mellitus; and COPD: chronic obstructive pulmonary disease.
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A total of 160 patients (103 [64.8%] male and the average age
was 62.4 11.5) fulﬁlled the inclusion criteria. A total number of 46
(28.7%) and 31 (19.4%) patients had postoperative morbidity and
surgery related complications, respectively (Table 1).
The univariate and multivariate analyses revealed that no other
factors but ASA score was the only risk factor for overall morbidity
(p ¼ 0.021 and 0.033 in analyses, respectively) (Table 2). An anas-
tomotic leak was observed in 17 (10.6%). A univariate analysis
showed that the incidence of an anastomotic leak was increasing in
patients received a D2 dissection (p ¼ 0.039), but there was not a
statistically signiﬁcant risk factor for this complication in multivar-
iate analysis (Table 3). Current study denied exposing a signiﬁcant
risk factor for predicting the risk for surgical site infection withTable 4
Univariate and multivariate analyses of the risk factors that may affect surgical site infec
n (%) Present Absent
Age
70 50 (31.2%) 2 (4%) 49 (96%)
<70 110 (68.7%) 6 (5.4%) 81 (94.6%)
Gender
Male 103 (64.8%) 6 (6.8%) 96 (93.2%)
Female 57 (35.2%) 2 (1.7%) 56 (98.3%)
Albumin level
3.5 37 (23.1%) 2(5.4%) 35 (94.6%)
<3.5 123 (76.9%) 6 (4.9%) 117 (95.1%)
Severe anemia
Absent 43 (26.9%) 1 (2.3%) 42 (97.7%)
Present 117 (73.1%) 7 (6%) 110 (94%)
ASA score
1e2 91 (56.9%) 3(1.1%) 88 (98.9%)
3e4 69 (43.1%) 5 (10.1%) 64 (89.9%)
Neoadjuvant chemotherapy
Required 15 (9.3%) 1 (6.7%) 14 (93.3%)
Not required 145 (90.7%) 7 (4.2%) 138 (95.8%)
DM
Present 24 (15%) 2 (8.3%) 22 (91.7%)
Absent 136 (85%) 6 (4.4%) 130 (95.6%)
Hypertension
Present 39 (24.4%) 1 (2.6%) 38 (97.4%)
Absent 121 (75.6%) 7 (5.8%) 114 (94.2%)
COPD
Present 8 (5%) 1 (12.5%) 7 (87.5%)
Absent 152 (95%) 7 (4.6%) 145 (95.4%)
Intraoperative transfusion
Required 69 (43.2%) 4 (5.8%) 65 (94.2%)
Not required 91 (56.8%) 4 (4.4%) 87 (95.6%)
Tumor localization
Proximal 65 (40.6%) 4 (6.1%) 61 (93.9%)
Distal 95 (59.4%) 4 (4.2%) 91 (95.8%)
Tumor stage
I 23 (14.4%) 2 (8.7%) 21 (91.3%)
II 38 (23.8%) 2 (5.3%) 36 (94.7%)
III 48 (30%) 2 (4.2%) 46 (95.8%)
IV 51 (31.8%) 2 (3.9%) 49 (96.1%)
Operation time
180 79 (49.4%) 2 (2.5%) 77 (97.5%)
<180 81 (50.6%) 6 (7.4%) 75 (92.6%)
Dissection width
D1 118 (73.7%) 3 (2.5%) 115 (97.5%)
D2 42 (26.3%) 5 (11.9%) 37 (88.1%)
Resection pattern
Subtotal 62 (38.7%) 2 (3.2%) 60 (96.8%)
Total 98 (61.3%) 6 (6.1%) 92 (93.9%)
Additional organ resection
Present 85 (53.1%) 7 (8.2%) 78 (91.8%)
Absent 75 (46.9%) 1 (1.3%) 74 (98.7%)
Reconstruction type
Roux-en Y 129 (80.6%) 7 (5.4%) 122(94.6%)
Omega 31 (19.4%) 1 (3.2%) 30(96.8%)
Abbreviations: ASA: anesthesia risk score deﬁned by American Anesthesiology Associatieither a univariate or a multivariate analysis (Table 4). Hospitaliza-
tion period was lengthened in patients who received a neoadjuvant
chemotherapy (p ¼ 0.041), a D2 dissection (p ¼ 0.028) or additional
organ resection (p ¼ 0.032) in univariate analysis, but multivariate
analysis did not conﬁrm these ﬁndings (Table 5). Although univar-
iate analysis revealed that age over 70 (p ¼ 0.008), ASA score
(p ¼ 0.018), operation time (p ¼ 0.032), D2 dissection (p ¼ 0.026)
and type of anastomosis (p ¼ 0.023) were effecting the risk for 30-
day mortality, multivariate analysis showed that age was the only
risk factor for postoperative early deaths (p ¼ 0.005) (Table 6).
4. Discussion
It is important for a surgeon to estimate morbidity and mortality
risks of gastric carcinoma surgeries before the surgery. Thistions.
Univariate p Multivariate p Wald Odds ratio
0.696
0.161 0.130 2.295 0.18
0.465
0.079 0.997 0.001 0.008
0.293
0.756
0.067 0.054 3.724 5.011
0.966
0.318
0.742
0.854
0.821
0.971
0.934
0.503
0.856
0.183 0.162 1.96 3.129
on; DM: diabetes mellitus; and COPD: chronic obstructive pulmonary disease.
Table 5
Univariate and multivariate analyses of the risk factors that may affect hospitalization period.
n (%) <10 days 10 days Univariate p Multivariate p Wald Odds ratio
Age
70 50 (31.2%) 24 (48%) 26 (52%) 0.230 0.763 0.091 1.126
<70 110 (68.7%) 64 (59.1%) 46 (40.9%)
Gender
Male 103 (64.8%) 57 (56.3%) 46 (43.7%) 0.908
Female 57 (35.2%) 31 (54.4%) 26 (45.6%)
Albumin level
3.5 37 (23.1%) 17 (45.9%) 20 (54.1%) 0.207 0.468 0.528 0.739
<3.5 123 (76.9%) 71 (58.5%) 52 (41.5%)
Severe anemia
Absent 43 (26.9%) 21 (48.8%) 22 (51.2%) 0.342
Present 117 (73.1%) 67 (58.1%) 50 (41.9%)
ASA score
1e2 91 (56.9%) 54 (60.4%) 37 (39.6%) 0.205 0.465 0.534 1.308
3e4 69 (43.1%) 34 (49.3%) 35 (50.7%)
Neoadjuvant chemotherapy
Required 15 (9.3%) 12 (80%) 3 (20%) 0.041 0.053 3.756 3.946
Not required 145 (90.7%) 76 (52.4%) 69 (47.6%)
DM
Present 24 (15%) 13 (54.2%) 11 (45.8%) 0.929
Absent 136 (85%) 75 (55.9%) 61 (44.1%)
Hypertension
Present 39 (24.4%) 20 (51.3%) 19 (48.7%) 0.591
Absent 121 (75.6%) 68 (57.1%) 53 (42.9%)
COPD
Present 8 (5%) 4 (50%) 4 (50%) 0.771
Absent 152 (95%) 84 (55.9%) 68 (44.1%)
Intraoperative transfusion
Required 69 (43.2%) 32 (46.4%) 37 (53.6%) 0.056 0.214 1.544 1.581
Not required 91 (56.8%) 56 (62.6%) 35 (37.4%)
Tumor localization
Proximal 65 (40.6%) 36 (55.4%) 29 (44.6%) 0.936
Distal 95 (59.4%) 52 (55.8%) 43 (44.2%)
Tumor stage
I 23 (14.4%) 14 (60.9%) 9 (39.1%) 0.559
II 38 (23.8%) 22 (57.9%) 16 (42.1%)
III 48 (30%) 24 (52.1%) 24 (47.9%)
IV 51 (31.8%) 28 (54.9%) 23 (45.1%)
Operation time
180 79 (49.4%) 44 (56.9%) 35 (43.1%) 0.861
<180 81 (50.6%) 44 (54.3%) 37 (45.7%)
Dissection width
D1 118 (73.7%) 71 (60.1%) 47 (39.9%) 0.028 0.068 3.324 2.212
D2 42 (26.3%) 17 (40.5%) 25 (59.5%)
Resection pattern
Subtotal 62 (38.7%) 37 (61.3%) 25 (38.7%) 0.344
Total 98 (61.3%) 51 (52.1%) 47 (47.9%)
Additional organ resection
Present 85 (53.1%) 40 (48.2%) 45 (51.8%) 0.032 0.203 1.621 1.665
Absent 75 (46.9%) 48 (64%) 27 (36%)
Reconstruction type
Roux-en Y 129 (80.6%) 75 (58.9%) 54 (41.1%) 0.103 0.072 3.237 2.269
Omega 31 (19.4%) 13 (41.9%) 18 (58.1%)
Abbreviations: ASA: anesthesia risk score deﬁned by American Anesthesiology Association; DM: diabetes mellitus; and COPD: chronic obstructive pulmonary disease.
Bold font style represents statistically signiﬁcant difference between groups, p < 0.05.
S. Vural et al. / International Journal of Surgery 11 (2013) 1103e1109 1107
ORIGINAL RESEARCHestimation is important to deﬁne whether the patient is suitable for
surgery or not, if a surgery is necessary which procedure should be
appliedandhowtogive the informationabout the risksof the surgery
to the patients when receiving approval. Moreover, classifying pa-
tients based on operative risks leads the surgeon to choose preop-
erative and postoperative cares. Accordingly, an operation with the
possible lowest postoperativemorbidity riskmay be considered to be
appropriate for a patient who has serious comorbidity. Yet, the
important pointhere is that theoperation to becarriedout shouldnot
lower the life expectancy of the patient more than other operation
options. The surgeon’s art is important to strike the right balance.19
A series of scoring systems were used to deﬁne the preoperative
morbidity and mortality risks of gastric carcinoma. The most
frequently used scoring system is ASA score which has been
developed by anesthesiologists and actually deﬁnes the risks ofanesthesia. It has been proven that ASA score is a really good in-
dicator to estimate postoperativemortality in gastric carcinomas. In
gastric carcinomas, the other two valid scoring systems which are
highly complicated are POSSUM (Physiologic and Operative
Severity Score for the enumeration of Mortality and Morbidity) and
E-PASS (Estimation of Physiologic Ability and Surgical Stress)
scoring systems. However, the precise value of these scoring sys-
tems remains controversial. Bollschweiler et al., have evaluated
POSSUM scoring system in a group of patients undergoing a D2
dissection for gastric cancer and have concluded that this system is
not useful to estimate postoperative conditions before the sur-
gery.20 In contrast, others have found that postoperative POSSUM
score and postoperative early period mortality was correlated with
each other.21 In addition, E-PASS scoring system was adapted for
gastric carcinoma surgery and concluded to be helpful in order to
Table 6
Univariate and multivariate analyses of the risk factors that may affect mortality.
n (%) Dead Alive Univariate p Multivariate p Wald Odds ratio
Age
70 50 (31.2%) 11 (22%) 39 (78%) 0.008 0.05 3.811 3.170
<70 110 (68.7%) 8 (7.3%) 81 (92.7%)
Gender
Male 103 (64.8%) 12 (11.6%) 91 (88.4%) 0.906
Female 57 (35.2%) 7 (12.3%) 50 (87.7%)
Albumin level
3.5 37 (23.1%) 6 (16.2%) 31 (83.8%) 0.352
<3.5 123 (76.9%) 13 (10.6%) 110 (89.4%)
Severe anemia
Absent 43 (26.9%) 6 (13.9%) 37 (86.1%) 0.622
Present 117 (73.1%) 13 (11.1%) 104 (88.9%)
ASA score
1e2 91 (56.9%) 6 (6.6%) 85 (93.4%) 0.018 0.105 2.625 2.726
3e4 69 (43.1%) 13 (18.8%) 56 (81.2%)
Neoadjuvant chemotherapy
Required 15 (9.3%) 1 (6.7%) 14 (93.3%) 0.512
Not required 145 (90.7%) 18 (12.4%) 127 (87.6%)
DM
Present 24 (15%) 5 (20.8%) 19 (79.2%) 0.141 0.288 1.129 2.061
Absent 136 (85%) 14 (10.3%) 122 (89.7%)
Hypertension
Present 39 (24.4%) 4 (10.2%) 35 (89.8%) 0.719
Absent 121 (75.6%) 15 (12.4%) 106 (87.6%)
COPD
Present 8 (5%) 2 (25%) 6 (75%) 0.239 0.873 0.026 1.168
Absent 152 (95%) 17 (11.2%) 135 (88.8%)
Intraoperative transfusion
Required 69 (43.2%) 10 (14.5%) 59 (85.4%) 0.373
Not required 91 (56.8%) 9 (9.9%) 82 (91.1%)
Tumor localization
Proximal 65 (40.6%) 11 (16.9%) 54 (83.1%) 0.103 0.639 0.220 0.768
Distal 95 (59.4%) 8 (8.4%) 87 (91.6%)
Tumor stage
I 23 (14.4%) 4 (17.4%) 19 (82.6%) 0.470
II 38 (23.8%) 5 (13.1%) 33 (86.9%)
III 48 (30%) 4 (8.3%) 44 (91.7%)
IV 51 (31.8%) 6 (11.8%) 45 (88.2%)
Operation time
180 79 (49.4%) 5 (6.3%) 74(93.7%) 0.032 0.098 2.731 2.841
<180 81 (50.6%) 14 (17.3%) 67 (82.7%)
Dissection width
D1 118 (73.7%) 10 (8.5%) 108 (91.5%) 0.026 0.307 1.044 0.936
D2 42 (26.3%) 9 (21.4%) 33 (78.6%)
Resection pattern
Subtotal 62 (38.7%) 5 (8.1%) 57 (91.95) 0.236 0.759 0.094 1.442
Total 98 (61.3%) 14 (14.3%) 84 (85.7%)
Additional organ resection
Present 85 (53.1%) 13 (15.3%) 72 (84.7%) 0.155 0.679 0.171 0.762
Absent 75 (%46.9) 6 (%8) 69 (%92)
Reconstruction type
Roux-en Y 129 (80.6%) 19 (14.7%) 110 (85.3%) 0.023 0.998 0.001 0.001
Omega 31 (19.4%) 0 (0) 31 (100%)
Abbreviations: ASA: anesthesia risk score deﬁned by American Anesthesiology Association; DM: diabetes mellitus; and COPD: chronic obstructive pulmonary disease.
Bold font style represents statistically signiﬁcant difference between groups, p< 0.05.
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of these scoring systems remains the major limitation on the
widespread use of them, thus many studies have decided to
calculate the risk factors for complications and mortality. In English
MRC data, which was a prospective randomized multicenter study,
the relationships between the width of dissection and post-
operative morbidity and mortality were evaluated. These data
revealed that postoperative early period mortality and morbidity
were increasing in patients who had D2 dissection or wider re-
sections including splenectomy and/or distal pancreatectomy.16
Similar results were also shown in other prospective randomized
trials or retrospective large volume analyses comparing the out-
comes of D1 and D2 dissections, and width of dissection, older age,
additional organ resection, Billroth 2 reconstruction pattern, ASAscore, hypoalbuminemia, resection for palliation were stated as the
independent risk factors for mortality and morbidity.23e26
In our study postoperative general morbidity rate was found as
around 29% and early mortality rate was approximately 12%, which
may be accepted as compatible with two important European
studies.14e17 In the current study, although D2 dissection was an
independent risk factor in univariate analysis as it increased surgery
related complications, particularly anastomotic leakage, hospitali-
zation period and 30-day mortality, multivariate analysis denied
revealing disadvantages of wider dissection, which was consistent
with the Italian studyandmost of the retrospective broad series.14e17
Current study also questioned the factors which lengthen the
hospitalization period, and revealed that although additional
organ resection, whichwas an indicator correlatedwith thewidth of
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ORIGINAL RESEARCHsurgery, was an independent factor in univariate analysis, multivar-
iate calculation did not conﬁrm this ﬁnding. In addition, multivariate
analyses revealed that higher ASA scores and older age were asso-
ciated with increased overall morbidity and 30-day mortality rates,
respectively. In our opinion, these are signiﬁcant ﬁndings, which are
also consistentwith the other studies andmay have a key role for the
surgeon during the decision making for the patients with gastric
cancer.
Current study may be criticized to include some limitations,
mostly related to its retrospective design and since include the data
of a single institution compared with studies conducted in Far East.
However, we believe that similar studies as ours belonged to non-
specialized centers with acceptable volumes of patients are needed
to be discussed, since for most of the patients in our country and all
over the world gastric carcinoma surgeries have been carried out in
this kind of institutions.
Considering the information regarding this single center retro-
spective study, wemay conclude that early morbidity andmortality
are not rare after gastric cancer surgery with curative intent. We
believe that it may be logical for the surgeons to consider patient
related factors including age and ASA score during the decision
making for the treatment in patients with gastric cancer, since
these parameters were shown to be independent risk factors for
postoperative 30-day mortality and overall morbidity in multivar-
iate analyses in the current study.
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